Idorsia is a turnaround bet with explosive potential but high risks. QUVIVIQ (Idorsia’s insomnia pills) is showing real traction, but the path to profitability remains long.
For investors with a high risk tolerance who believe in the recovery of European biotechs, it could be an interesting opportunity with appropriate position sizing.
What do you think?
Are you willing to accept the risk for the potential upside, or would you prefer to wait for greater visibility on profitability?